Effect of clopidogrel added to aspirin in patients with atrial fibrillation

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Atrial fibrillation (AF) patients at risk of stroke often cannot use vitamin K antagonists (VKAs).
• Aspirin is a common alternative, but its efficacy in preventing vascular events in AF is limited.
• Investigating combination therapy for AF patients unsuitable for VKAs is crucial.

Purpose of the Study:

• To evaluate if adding clopidogrel to aspirin reduces vascular events in AF patients.
• To assess the safety profile of clopidogrel plus aspirin in this patient population.

Main Methods:

• A randomized trial involving 7554 AF patients at increased stroke risk, unsuitable for VKAs.
• Patients received daily clopidogrel (75 mg) or placebo, in addition to aspirin.
• Primary outcome: composite of stroke, myocardial infarction, systemic embolism, or vascular death.

Main Results:

• Clopidogrel plus aspirin reduced major vascular events by 11% (relative risk, 0.89; P=0.01).
• Stroke incidence significantly decreased with clopidogrel (2.4% vs. 3.3% per year; P<0.001).
• Major hemorrhage risk increased by 57% with clopidogrel (2.0% vs. 1.3% per year; P<0.001).

Conclusions:

• For AF patients unsuitable for VKAs, clopidogrel plus aspirin reduces major vascular events, primarily stroke.
• The combination therapy leads to a significant increase in major hemorrhage risk.
• Risk-benefit assessment is essential when considering clopidogrel addition to aspirin in AF management.